Clinical Trial Update: Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants [Phase 3]

View source ↗

Summary

This entry reports the completion of a Phase 3 study evaluating a 13-valent pneumococcal conjugate vaccine in infants and the posting of results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Pneumococcal Disease
• Pneumococcal Disease
• Pneumonia

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Vaccines, Pneumococcal | Phase 3 | Status: COMPLETED | Results posted: 2012-08-15